Career Enhancement Program

职业提升计划

• 批准号: 10494113
• 负责人: KEVIN M. SHANNON
• 金额: $ 9.39万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10494113
• 关键词: Acceleration; Address; Area; Award; Basic Science; California; Cancer Biology; Cancer Center; Child; Clinical; Clinical Investigator; Clinical Sciences; Communication; Communities; Data; Development; Discipline; Disease; Education; Ensure; Extramural Activities; Faculty; Feedback; Foundations; Funding; Funding Opportunities; Future; Goals; Health Sciences; Historically Black Colleges and Universities; Human; Human Development; Indiana; Individual; Infrastructure; Institution; International; Knowledge; Leadership; Link; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Mentors; Mentorship; Mission; Monitor; Mutation; NF1 gene; NF1 mutation; National Cancer Institute; Nature; Neurofibromatoses; Pathology; Pediatric Hospitals; Pediatric Oncology; Pediatric Oncology Group; Philadelphia; Pre-Clinical Model; Process; Professional Organizations; Program Development; Request for Applications; Research; Research Personnel; Resources; Role; San Francisco; Schedule; Science; Scientist; Sex Orientation; Signal Transduction; Site; Societies; Structure; Talents; Texas; Textiles; Therapeutic; Therapeutic Trials; Training; Training Programs; Translational Research; Underrepresented Minority; Underrepresented Populations; Universities; Work; anticancer research; base; cancer therapy; career; career development; clinical outcome assessment; clinical translation; design; developmental disease; disability; early-career faculty; effective therapy; efficacy validation; faculty support; hyperactive Ras; innovation; instructor; meetings; member; minority investigator; neoplasm therapy; neuro-oncology; next generation; pharmacokinetics and pharmacodynamics; preclinical study; professor; programs; racial and ethnic; recruit; senior faculty; skills; success; translational scientist; tumor

ABSTRACT– CAREER ENCHANCEMENT PROGRAM The DHART SPORE Career Enhancement Program (CEP) supports faculty at the Instructor and Assistant Professor levels to engage in translational research focused on NF1/Rasopathy disorders and cancer. The primary goal of the CEP is to advance the careers of early stage investigators who are developing innovative research related to the goal of implementing more effective and less toxic therapies for cancers characterized by NF1/Ras. The multi-institutional nature of this SPORE leverages a large and talented pool of early career faculty from multiple disciplines. Each institution views the CEP as a vehicle for recruiting and advancing the careers of early stage translational scientists. Collectively, they have committed $1.3 million to the current award and $1.65 million to the renewal to support the Developmental Programs of the DHART SPORE (CEP and DRP). The Specific Aims of the CEP are to: (1) support early stage investigators as they develop innovative research programs that contribute new knowledge to NF1-related cancer research while generating preliminary data that will allow successful future independent extramural funding; (2) provide early stage researchers with training that will equip them with essential skills and knowledge for success as independent investigators; and, (3) mentor early stage translational researchers through regularly scheduled one-on-one mentor meetings and a structured Individual Development Program (IDP) to facilitate integration into the fabric of the SPORE. The CEP has a special emphasis on supporting the recruitment of underrepresented minority investigators (URM). The DHART SPORE will link vertically and horizontally with diversity programs at all of the consortium institutions and ensure maximum exposure of the CEP mentorship and funding opportunities to URM across the seven DHART SPORE sites. Further, requests for applications (RFA) will be shared with Historically Black Colleges and Universities and professional organizations representing communities under- represented in biomedical science. RFAs are already sent outside of the DHART SPORE sites via the Children’s Tumor Foundation and Neurofibromatosis Therapeutic Acceleration Program. We are expanding this recruitment effort to include the Society for Neuro-Oncology, RASopathies Network USA, the Children’s Oncology Group. The goal is to fund two CEP proposals per year ($50,000 - $75,000/proposal). Requests for applications will be announced twice a year via broad communications to all groups listed above to maximize opportunities for recruitment of diverse scientists and science. CEP opportunities will also be highlighted at professional meetings throughout the year. Applications for CEP support will be evaluated through a competitive process with review by a Developmental Programs Steering Committee comprised of senor scientists from the DHART SPORE with oversight and guidance from the SPORE External and Internal Advisory Boards.

抽象-职业提升计划 DHART孢子职业提升计划(CEP)支持讲师和助理的教员 教授水平，从事翻译研究，重点是NF1/类风湿疾病和癌症。这个 CEP的主要目标是促进正在开发创新能力的早期调查人员的职业生涯 与为癌症实施更有效和毒性更低疗法的目标有关的研究 由NF1/RAS。这种孢子的多机构性质利用了一大批有才华的早期职业 来自多个学科的教师。每个机构都将CEP视为招募和推进 早期翻译科学家的职业生涯。他们总共承诺了130万美元用于目前的 奖励和165万美元用于支持达特孢子发展计划(CEP)的更新 和DRP)。CEP的具体目标是：(1)支持早期调查人员的发展 创新研究计划，为NF1相关癌症研究贡献新知识，同时产生 (2)提供早期阶段的初步数据，使今后能够成功地获得独立的外部资金； 为研究人员提供培训，使他们具备独立取得成功所需的基本技能和知识 研究人员；以及，(3)通过定期安排的一对一指导早期翻译研究人员 导师会议和结构化的个人发展计划(IDP)，以促进与交换矩阵的集成 孢子的种类。执行委员会特别强调支持招募任职人数偏低的少数群体。 调查人员(URM)。达哈特孢子将在垂直和水平上与所有 财团机构，并确保最大限度地利用CEP的指导和供资机会 在七个Dhart孢子遗址上进行了URM。此外，应用程序请求(RFA)将与 历史上，黑人学院和大学以及代表以下社区的专业组织- 在生物医学科学中具有代表性。RFA已经通过DHART孢子站点发送到外部 儿童肿瘤基金会和神经纤维瘤病治疗加速计划。我们正在扩张 这项招募工作包括神经肿瘤学学会、美国Rasopathies网络、儿童 肿瘤学小组。目标是每年资助两个CEP提案(每个提案50,000-75,000美元)。申请 申请将每年公布两次，通过广泛的沟通，所有上述小组，以最大限度地 为招募不同的科学家和科学提供机会。CEP机会也将在以下会议上重点介绍 全年专业会议。CEP支持的申请将通过 竞争过程，由参议员组成的发展计划指导委员会进行审查 来自达特孢子的科学家在孢子外部和内部的监督和指导下 顾问委员会。